IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF) (AIMI-HF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01288560|
Recruitment Status : Recruiting
First Posted : February 2, 2011
Last Update Posted : May 30, 2018
Medical imaging is one of the fastest growing sectors in health care and increases in utilization underscore the need to ensure imaging technology is developed and used effectively. Evaluation of the clinical and economic impact of such imaging lags behind the technology development. Heart failure (HF)represents the final common pathway for most forms of heart disease and morbidity and mortality remain high. There is a need to identify imaging approaches that have a positive impact on therapy decisions, patient outcomes and costs. As well as standard methods to evaluate new and emerging techniques to better test their potential in a clinical management setting. The OVERALL OBJECTIVES of the IMAGE-HF trial are 1) to determine the impact of emerging imaging strategies, on relevant clinical outcomes and decision making in patients with HF; 2) to establish standardization quality assurance (QA) measures and central databases in order to achieve reliable outcome driven research; 3) to apply this as a platform for evaluation of new and emerging imaging biomarkers in HF.
Project I-A: The PRIMARY OBJECTIVE OF AIMI-HF is to compare the effect of HF imaging strategies on the composite clinical endpoint of cardiac death, MI, resuscitated cardiac arrest and cardiac re-hospitalization (WHF, ACS, arrhythmia). Patients with an ischemic heart disease (IHD) etiology will follow HF imaging strategy algorithms according to the question(s) asked by the physicians (is there ischemia and/or viability), in agreement with their local practices for standard and alternative imaging.
Secondary objectives of AIMI-HF To compare the effect of HF imaging strategies on
- The incidence of revascularization procedures (PCI, CABG)
- LV remodeling: LV volumes, LVEF
- HF symptoms, NYHA class
- QOL (MLHFQ, the EQ5D)
- The evolution of serum prognostic markers in HF (e.g. BNP, RDW, hs-cTnT, hs-CRP)
- Health economics: Costs estimated through regression analysis and cost effectiveness assessed through decision modeling.
- The safety of imaging tests measured by cumulative radiation, adverse reactions to imaging contrast agents and stress testing agents will also be determined.
- The evolution of renal function (eGFR) and LV remodeling-associated biomarkers (e.g. PIIINP, OPN).
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure Coronary Artery Disease Ischemic Cardiomyopathy Non-ischemic Cardiomyopathy||Other: Advanced cardiac imaging Other: Standard Cardiac Imaging||Phase 4|
Hide Detailed Description
Among patients with coronary artery disease and HF, mortality rates range from 10-60% at 1 year. Many trials have demonstrated benefit of revascularization in patients with ischemic heart disease (IHD) and LV dysfunction. Some criteria, such as severe angina or left main coronary artery stenosis may indicate the need for surgical therapy for HF patients; however, a large number of patients fall into a gray zone without clear evidence for benefit from surgical intervention. The need remains for approaches that can help better define and select the HF patients most likely to benefit from revascularization; which could be either surgical or percutaneous intervention.
Increasingly over the past three decades, information describing cardiac structure, perfusion, hemodynamics, and metabolism obtained from noninvasive cardiac imaging studies has been used to guide management decisions for patients with HF.
AIMI-HF is part of a large Canadian team grant IMAGE-HF (Imaging Modalities to Assist with Guiding therapy and the Evaluation of patients with Heart Failure) involving 3 parallel randomized trials addressing the role of imaging in HF patients according to HF etiology.
Primary Hypothesis of AIMI-HF:
In patients with HF due to IHD with LVEF less than or equal to 45%, a management algorithm that applies alternative imaging strategies (PET or CMR) achieves a better clinical outcome measured as the composite clinical endpoint (CCE) of cardiac death, MI, resuscitated cardiac arrest and cardiac re-hospitalization (WHF, ACS, arrhythmia) than an approach with "standard care".
Secondary Hypotheses of AIMI-HF:
i) Compared to standard care, in patients with HF due to IHD with LVEF ≤ 45%, a management algorithm that applies alternative imaging modalities (PET or CMR) achieves: a) more efficient use of revascularization procedures with similar complication rates than standard care imaging strategies b) better LV remodeling (including favorable evolution of serum markers associated with LV remodeling e.g. PIIINP, OPN) c) better HF and angina symptom reduction, d) better QoL, measured using MLHFQ and EQ5D, e) more favorable evolution of selected serum markers of prognosis in HF (e.g. BNP, RDW, hs-cTnT, hs-CRP) and f) is economically attractive in patients with HF due to IHD with LVEF<45%.
ii) In patients with HF due to IHD with LVEF ≤ 45%, a HF management algorithm that applies PET achieves a better primary composite clinical endpoint (CCE) and secondary outcomes (revascularizations, remodeling, QoL, Cost efficiency) compared to one that applies CMR.
iii) Renal function impairment is a known independent predictor of cardiovascular events in HF. Renal function may influence revascularisation decisions and its evolution could be modified by revascularisation procedures.
AIMI-HF is the IMAGE-HF Project 1-A trial; it is a prospective comparative effectiveness study to compare the effect of HF imaging strategies in patients with HF due to IHD. Eligible patients will have LV systolic dysfunction due to IHD where evaluation of ischemia and viability is relevant. Patients will be prospectively randomized to standard (SPECT) versus advanced (PET or CMR) imaging. Patients who meet inclusion criteria but cannot be randomized due to clinical management decisions, yet undergo standard or advanced imaging (SPECT, PET/CT or CMR), will be entered into a registry. Based on site screening logs, patients who could not be randomized, who met all other inclusion criteria and underwent standard or advanced imaging, will be retrospectively enrolled, from the date of original HREB approval, into the study as registry participants. Registry recruitment will be monitored to ensure a balanced recruitment for each modality registry.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1511 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) Project I-A of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||June 2019|
Active Comparator: Advanced cardiac imaging (PET/CT or CMR)
Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
Other: Advanced cardiac imaging
Active Comparator: Standard cardiac imaging (SPECT)
Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
Other: Standard Cardiac Imaging
Other Name: SPECT
- The time to event of the composite clinical endpoint. [ Time Frame: 3, 12 and 24 months ]
For the primary analysis, the time-to-event of the composite clinical endpoint of cardiac death, MI, arrest and cardiac re-hospitalization
(WHF, ACS, arrhythmia) will be compared between the advanced modality (PET or CMR) to an approach with standard care using SPECT imaging using survival analysis. Kaplan-Meier survival curves of the primary endpoint will be compared between the advanced and standard modalities with the log-rank test. In addition for the primary hypothesis, a SPECT registry will be considered in order to make the allocation between the advanced and standard modalities 1:1.
- Change in Left ventricular ejection fraction, NYHA symptom class, Quality of Life and related resource utilization [ Time Frame: 3, 12 and 24 months ]For the secondary outcomes PCI, CABG, HF symptoms and NYHA class, chi-square tests will be used to compare the advanced and standard imaging technologies; logistic regression analysis will be used for adjusting any pertinent baseline differences identified. For the secondary outcomes LVEF, MLHFQ and EQ5D, analysis of variance will be used to compare trends over time between the advanced and standard technologies. Analysis of covariance will be used for adjusting any pertinent baseline differences identified.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01288560
|Contact: Linda M. Garrard, RN, BScN||613-696-7000 ext email@example.com|
|United States, Massachusetts|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States|
|Contact: Marcelo DiCarli, MD|
|Diagnostico Maipu por Imagenes||Recruiting|
|Buenos Aires, Argentina|
|Contact: Roxanna Campisi, MD|
|Diagnostico Medico Orono||Recruiting|
|Contact: Maria Cecilia Ziadi, MD|
|Quanta Diagnóstico e Terapia||Recruiting|
|Contact: Joao Vitola|
|University of Calgary||Recruiting|
|Calgary, Alberta, Canada|
|Contact: James White, MD|
|Principal Investigator: James White, MD|
|University of Alberta||Recruiting|
|Edmonton, Alberta, Canada|
|Contact: Ian Paterson, MD|
|Principal Investigator: Ian Paterson, MD|
|Canada, British Columbia|
|Vancouver, British Columbia, Canada|
|Contact: Jonathan Leipsic, MD|
|University of Manitoba||Recruiting|
|Winnipeg, Manitoba, Canada|
|Contact: Malek Kass, MD|
|Sub-Investigator: Malek Kass, MD|
|Sub-Investigator: James Tan, MD|
|Canada, Nova Scotia|
|Halifax, Nova Scotia, Canada|
|Contact: Miroslaw Rajda, MD Miroslaw.Rajda@cdha.nshealth.ca|
|Principal Investigator: Miroslaw Rajda, MD|
|Sub-Investigator: James Clarke, MD|
|Hamilton, Ontario, Canada|
|Contact: Vikas Tandon firstname.lastname@example.org|
|Principal Investigator: Vikas Tandon, MD|
|Sub-Investigator: Karen Gulenchyn, MD|
|London Health Sciences Centre||Suspended|
|London, Ontario, Canada|
|University of Ottawa Heart Institute||Recruiting|
|Ottawa, Ontario, Canada, K1Y 4W7|
|Contact: Linda M Garrard, RN, BScN 613-696-7000 ext 14192 email@example.com|
|Sub-Investigator: Rob S. Beanlands, MD, FRCP C|
|Principal Investigator: Lisa Mielniczuk, MD, FRCP C|
|Sub-Investigator: George A Wells, PhD|
|Sub-Investigator: Robert A. deKemp, PhD|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada|
|Contact: Kim Connelly, MD 14168645201 firstname.lastname@example.org|
|Principal Investigator: Kim Connelly, MD|
|Sub-Investigator: Michael Freeman, MD|
|Sub-Investigator: Howard Leong-Poi, MD|
|Sunnybrook Health Sciences Centre||Recruiting|
|Toronto, Ontario, Canada|
|Contact: Graham Wright, MD (416)480-6869 email@example.com|
|Principal Investigator: Graham Wright, MD|
|Principal Investigator: Kim Connelly, MD|
|Sub-Investigator: Charles Cunningham Cunningham, MD|
|Montreal Heart Institute||Recruiting|
|Montreal, Quebec, Canada|
|Contact: Eileen O'Meara, MD|
|Principal Investigator: Eileen O'Meara, MD|
|Sub-Investigator: Jean-Claude Tardif, MD|
|University of Laval||Recruiting|
|Quebec City, Quebec, Canada|
|Contact: Philippe Pibarot, MD|
|Principal Investigator: Philippe Pibarot, MD|
|Université de Sherbrooke||Suspended|
|Sherbrooke, Quebec, Canada|
|Helsinki University Central Hospital,||Recruiting|
|Contact: Mika Laine, MD 358 405 245735 Mika.Laine@hus.fi|
|Principal Investigator: Mika Laine, MD|
|University of Kuopio||Recruiting|
|Contact: Juha Hartikainen, MD 044-711 3945 Juha.Hartikainen@kuh.fi|
|Principal Investigator: Juha Hartikainen, MD|
|Sub-Investigator: Satu Karkkainen, M D|
|University of Turku||Recruiting|
|Contact: Juhani Knuuti, MD|
|Principal Investigator: Juhani Knuuti, MD|
|Sub-Investigator: Heikki Ukkonen, MD|
|Sub-Investigator: Seppo Yla-Herttuala, MD|
|Study Director:||Rob S Beanlands, MD, FRCP C||Ottawa Heart Institute Research Corporation|
|Principal Investigator:||Eileen O'Meara, MD||Montreal Heart Institute|
|Principal Investigator:||Lisa Mielniczuk, MD||Ottawa Heart Institute Research Corporation|